Drug Profile
Research programme: apoptosis stimulants - Bionexis
Latest Information Update: 07 Mar 2011
Price :
$50
*
At a glance
- Originator Bionexis
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Rheumatoid arthritis
Most Recent Events
- 07 Mar 2011 No development reported - Preclinical for Cancer in France (unspecified route)
- 07 Mar 2011 No development reported - Preclinical for Rheumatoid arthritis in France (unspecified route)
- 31 Dec 2005 Preclinical trials in Cancer in France (unspecified route)